Age associated memory impairment (AAMI) is a common condition characterized by mild memory decline that occurs in many adults as part of the normal aging process. AAMI appears to be highly frequent across different groups of individuals.
VIVIMIND™ is a patented product based on the naturally occurring ingredient homotaurine, which binds to A-beta proteins and reduces the deposition and toxic effects of these proteins in the brain.
Over 18 months Homotaurine reduces the loss of hippocampal volume by 68% compared to placebo. Homotaurine showed a 33% better result in cognitive performance tests (ADAS-cog) vs. placebo at 12 months.
Watch our Flash video to learn more about AAMI, how VIVIMIND™ works, and the underlying scientific principles and groundbreaking clinical studies that demonstrate the results of the patented VIVIMIND™ product.
VIVIMIND™ is currently commercially available in Canada and Italy and will soon be available in the Middle East, Greece and Cyprus. BELLUS Health is actively seeking to expand VIVIMIND™’s commercial reach throughout the world via strategic partnerships. To that end, BELLUS recently formed exclusive distribution partnerships in Canada with Advanced Orthomolecular Research Inc., in Italy with FB Health Inc., in the Middle East with the Agahan Group, in Israel with LevPharm, in Greece with Integris and in Taiwan with Lifenergy. BELLUS is currently in active partnership discussions with several parties for the rights to VIVIMIND™ in other territories.
(more…)
For inquiries regarding partnership opportunities in other territories please contact Tony Matzouranis, Vice President, Business Development at BELLUS Health by email tmatzouranis@bellushealth.com (more…)
Read More
| © BELLUS Health Inc. |
site by
visitEarth.ca